Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil

Background and aim: Paclitaxel (PTX) plus 5-fluorouracil (5-Fu) has become the standard chemotherapy for advanced gastric cancer (GC). Apatinib, a small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, improves outcomes in GC patients as a third-line treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhiyuan, Hu, Can, Chen, Shangqi, Zhang, Chunli, Yu, Jianfa, Wang, Xiaofeng, Lv, Hang, Cheng, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549793/
https://www.ncbi.nlm.nih.gov/pubmed/31213909
http://dx.doi.org/10.2147/CMAR.S196372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549793/
https://www.ncbi.nlm.nih.gov/pubmed/31213909
http://dx.doi.org/10.2147/CMAR.S196372

Ejemplares similares